Literature DB >> 24493287

Gene expression signature for biliary atresia and a role for interleukin-8 in pathogenesis of experimental disease.

Kazuhiko Bessho1, Reena Mourya, Pranavkumar Shivakumar, Stephanie Walters, John C Magee, Marepalli Rao, Anil G Jegga, Jorge A Bezerra.   

Abstract

UNLABELLED: Biliary atresia (BA) is a progressive fibroinflammatory obstruction of extrahepatic bile ducts that presents as neonatal cholestasis. Due to the overlap in clinical, biochemical, and histological features with other causes of cholestasis, the diagnosis requires an intraoperative cholangiogram. Thus, we determined whether diseased livers express a gene expression signature unique to BA. Applying stringent statistical analysis to a genome-wide liver expression platform of 64 infants with BA at the time of diagnosis, 14 age-appropriate subjects with intrahepatic cholestasis as diseased controls and seven normal controls, we identified 15 genes uniquely expressed in BA with an accuracy of 92.3%. Among these genes, IL8 and LAMC2 were sufficient to classify subjects with BA distinctly from diseased controls with an area under the curve of 0.934 (95% confidence interval [CI]: 0.84-1.03), sensitivity of 96.9%, and specificity of 85.7% using their combined first principal component. Direct measurement of interleukin (IL)8 protein in the serum, however, was not different between the two groups. To investigate whether the liver-restricted increase in IL8 was relevant to disease pathogenesis, we inactivated the signaling of IL8 homologs by genetic targeting of the Cxcr2 receptor in a murine model of experimental BA. Disruption of Cxcr2 shortened the duration of cholestasis, decreased the incidence of bile duct obstruction, and improved survival above wild-type neonatal mice.
CONCLUSION: The hepatic expression of IL8 and LAMC2 has high sensitivity for BA at diagnosis and may serve as a biomarker of disease, with an important role for the IL8 signaling in experimental BA.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24493287      PMCID: PMC4077977          DOI: 10.1002/hep.27045

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  33 in total

1.  Dendritic cells regulate natural killer cell activation and epithelial injury in experimental biliary atresia.

Authors:  Vijay Saxena; Pranavkumar Shivakumar; Gregg Sabla; Reena Mourya; Claire Chougnet; Jorge A Bezerra
Journal:  Sci Transl Med       Date:  2011-09-28       Impact factor: 17.956

Review 2.  Biliary atresia: will blocking inflammation tame the disease?

Authors:  Kazuhiko Bessho; Jorge A Bezerra
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

3.  Analysis of the biliary transcriptome in experimental biliary atresia.

Authors:  Elisa Carvalho; Cong Liu; Pranavkumar Shivakumar; Gregg Sabla; Bruce Aronow; Jorge A Bezerra
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

4.  Serum IL-6 and IL-8 in infants with biliary atresia in comparison to intrahepatic cholestasis.

Authors:  Amel A M El-Faramawy; Lerine B E El-Shazly; Amal A Abbass; Hend A B Ismail
Journal:  Trop Gastroenterol       Date:  2011 Jan-Mar

5.  Osteopontin upregulation in rotavirus-induced murine biliary atresia requires replicating virus but is not necessary for development of biliary atresia.

Authors:  Paula M Hertel; Sue E Crawford; Milton J Finegold; Mary K Estes
Journal:  Virology       Date:  2011-07-13       Impact factor: 3.616

6.  Association of serum interleukin-8 levels with the degree of fibrosis in infants with chronic liver disease.

Authors:  Valerio Nobili; Matilde Marcellini; Luigi Giovannelli; Elia Girolami; Flaminia Muratori; Germana Giannone; Rita Devito; Fabrizio De Benedetti
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-11       Impact factor: 2.839

7.  Degeneration of intrahepatic bile duct with lymphocyte infiltration into biliary epithelial cells in biliary atresia.

Authors:  T Ohya; T Fujimoto; H Shimomura; T Miyano
Journal:  J Pediatr Surg       Date:  1995-04       Impact factor: 2.545

8.  Usefulness of a scoring system in the interpretation of histology in neonatal cholestasis.

Authors:  Way Seah Lee; Lai Meng Looi
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

9.  Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Authors:  Virginia Moyer; Deborah K Freese; Peter F Whitington; Alan D Olson; Fred Brewer; Richard B Colletti; Melvin B Heyman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-08       Impact factor: 2.839

10.  ToppGene Suite for gene list enrichment analysis and candidate gene prioritization.

Authors:  Jing Chen; Eric E Bardes; Bruce J Aronow; Anil G Jegga
Journal:  Nucleic Acids Res       Date:  2009-05-22       Impact factor: 16.971

View more
  37 in total

1.  Regulation of epithelial injury and bile duct obstruction by NLRP3, IL-1R1 in experimental biliary atresia.

Authors:  Li Yang; Tatsuki Mizuochi; Pranavkumar Shivakumar; Reena Mourya; Zhenhua Luo; Sridevi Gutta; Jorge A Bezerra
Journal:  J Hepatol       Date:  2018-06-08       Impact factor: 25.083

2.  Glutathione antioxidant pathway activity and reserve determine toxicity and specificity of the biliary toxin biliatresone in zebrafish.

Authors:  Xiao Zhao; Kristin Lorent; Benjamin J Wilkins; Dylan M Marchione; Kevin Gillespie; Orith Waisbourd-Zinman; Juhoon So; Kyung Ah Koo; Donghun Shin; John R Porter; Rebecca G Wells; Ian Blair; Michael Pack
Journal:  Hepatology       Date:  2016-06-11       Impact factor: 17.425

3.  Identification of a plant isoflavonoid that causes biliary atresia.

Authors:  Kristin Lorent; Weilong Gong; Kyung A Koo; Orith Waisbourd-Zinman; Sara Karjoo; Xiao Zhao; Ian Sealy; Ross N Kettleborough; Derek L Stemple; Peter A Windsor; Stephen J Whittaker; John R Porter; Rebecca G Wells; Michael Pack
Journal:  Sci Transl Med       Date:  2015-05-06       Impact factor: 17.956

4.  Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia.

Authors:  Chatmanee Lertudomphonwanit; Reena Mourya; Lin Fei; Yue Zhang; Sridevi Gutta; Li Yang; Kevin E Bove; Pranavkumar Shivakumar; Jorge A Bezerra
Journal:  Sci Transl Med       Date:  2017-11-22       Impact factor: 17.956

5.  Preferential TNFα signaling via TNFR2 regulates epithelial injury and duct obstruction in experimental biliary atresia.

Authors:  Pranavkumar Shivakumar; Tatsuki Mizuochi; Reena Mourya; Sridevi Gutta; Li Yang; Zhenhua Luo; Jorge A Bezerra
Journal:  JCI Insight       Date:  2017-03-09

6.  Regulation of bile duct epithelial injury by hepatic CD71+ erythroid cells.

Authors:  Li Yang; Pranavkumar Shivakumar; Jeremy Kinder; Sing Sing Way; Bryan Donnelly; Reena Mourya; Zhenhua Luo; Jorge A Bezerra
Journal:  JCI Insight       Date:  2020-06-04

7.  Gene expression profiling of extrahepatic ducts in children with biliary atresia.

Authors:  Jiang Wang; Wei Wang; Rui Dong; Rui Zhao; Zhu Jin; Wenjun Shen; Shan Zheng
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 8.  Biliary Atresia in Children: Update on Disease Mechanism, Therapies, and Patient Outcomes.

Authors:  Swati Antala; Sarah A Taylor
Journal:  Clin Liver Dis       Date:  2022-06-25       Impact factor: 6.265

9.  Embryonic cholecystitis and defective gallbladder contraction in the Sox17-haploinsufficient mouse model of biliary atresia.

Authors:  Hiroki Higashiyama; Aisa Ozawa; Hiroyuki Sumitomo; Mami Uemura; Ko Fujino; Hitomi Igarashi; Kenya Imaimatsu; Naoki Tsunekawa; Yoshikazu Hirate; Masamichi Kurohmaru; Yukio Saijoh; Masami Kanai-Azuma; Yoshiakira Kanai
Journal:  Development       Date:  2017-04-21       Impact factor: 6.868

Review 10.  Biliary Atresia: Clinical and Research Challenges for the Twenty-First Century.

Authors:  Jorge A Bezerra; Rebecca G Wells; Cara L Mack; Saul J Karpen; Jay H Hoofnagle; Edward Doo; Ronald J Sokol
Journal:  Hepatology       Date:  2018-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.